Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Changes in Glucose Breath Test in Cystic Fibrosis Patients Treated With 1 Month of Lumacaftor/Ivacaftor.

Journal of pediatric gastroenterology and nutrition - 1 Jul 2022

Gabel Megan E, Wang Hongyue, Gelfond Daniel, Roach Christine, Rowe Steven M, Clancy John P, Sagel Scott D, Borowitz Drucy

Abstract excerpt

BACKGROUND: Alteration of the airway microbiota is a hallmark of cystic fibrosis (CF) pulmonary disease. Dysfunction of cystic fibrosis transmembrane regulator (CFTR) in the intestine also promotes changes in local microbiota such as small intestinal bacterial overgrowth (SIBO), which is common in CF. We evaluated whether therapy with the CFTR modulator combination lumacaftor/ivacaftor (luma/iva) has a beneficial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Aminopyridines

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Benzodioxoles

Share to Breath Tests

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Glucose

Share to Hydrogen

Share to Quinolones

Source

Identifiers

PMID: 35442228
DOI: 10.1097/MPG.0000000000003459

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Changes in Glucose Breath Test in Cystic Fibrosis Patients Treated With 1 Month of Lumacaftor/Ivacaftor.PMID 35442228Read ↗

Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory microbiota composition.Semantic proximity Read ↗

Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial.Semantic proximity Read ↗

The presence of cystic fibrosis-related diabetes modifies the sputum microbiome in cystic fibrosis diseaseSemantic proximity Read ↗

Longitudinal Profiling of the Intestinal Microbiome in Children with Cystic Fibrosis Treated with Elexacaftor-Tezacaftor-IvacaftorSemantic proximity Read ↗

Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal InflammationSemantic proximity Read ↗

Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.Semantic proximity Read ↗

Remodelling of cystic fibrosis respiratory microbiota in response to extended Elexacaftor–Tezacaftor–Ivacaftor therapySemantic proximity Read ↗

The Intestinal Microbiome and Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Emerging Themes in the Management of Gastrointestinal Manifestations of Cystic Fibrosis.Semantic proximity Read ↗

The altered gut microbiota in adults with cystic fibrosis.Semantic proximity Read ↗

Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation.Semantic proximity Read ↗

Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on the oropharyngeal metagenome in adolescents with cystic fibrosisSemantic proximity Read ↗

Reduced Intestinal Inflammation With Lumacaftor/Ivacaftor in Adolescents With Cystic Fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.